Next‐generation sequencing for BCR‐ABL1 kinase domain mutations in adult patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A position paper
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Next‐generation sequencing for
BCR‐ABL1
kinase domain mutations in adult patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A position paper
Authors
Keywords
-
Journal
Cancer Medicine
Volume 9, Issue 9, Pages 2960-2970
Publisher
Wiley
Online
2020-03-10
DOI
10.1002/cam4.2946
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1
- (2019) H. Pfeifer et al. LEUKEMIA
- Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia
- (2019) Delong Liu et al. Journal of Hematology & Oncology
- Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study
- (2019) Hagop M. Kantarjian et al. CANCER
- Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group
- (2019) Josep‐Maria Ribera et al. CANCER
- Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges
- (2019) Simona Soverini et al. Journal of Hematology & Oncology
- Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019
- (2019) Patrick A. Brown et al. Journal of the National Comprehensive Cancer Network
- Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study
- (2019) Aytug Kizilors et al. Lancet Haematology
- Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome–positive B‐precursor acute lymphoblastic leukemia
- (2019) Alessandro Rambaldi et al. CANCER
- Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study
- (2019) Simona Soverini et al. BLOOD
- Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper
- (2019) Simona Soverini et al. Journal of Hematology & Oncology
- Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia
- (2018) Carolina Pavlovsky et al. Future Oncology
- New Approaches to the Management of Adult Acute Lymphoblastic Leukemia
- (2018) Renato Bassan et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutational analysis in BCR - ABL1 positive leukemia by deep sequencing based on nanopore MinION technology
- (2017) Crescenzio F. Minervini et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2016) D. Hoelzer et al. ANNALS OF ONCOLOGY
- Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL
- (2016) Philippe Rousselot et al. BLOOD
- Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the
- (2016) Sebastian Giebel et al. CANCER
- A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study
- (2016) S. Chiaretti et al. HAEMATOLOGICA
- Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia
- (2016) C. Baer et al. HAEMATOLOGICA
- Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients
- (2016) S Soverini et al. LEUKEMIA
- Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients
- (2016) Simona Soverini et al. Oncotarget
- A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study
- (2016) S. Chiaretti et al. HAEMATOLOGICA
- Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia
- (2016) C. Baer et al. HAEMATOLOGICA
- Detection of BCR-ABL1 mutations that confer tyrosine kinase inhibitor resistance using massively parallel, next generation sequencing
- (2015) Philippe Szankasi et al. ANNALS OF HEMATOLOGY
- Patients with Philadelphia-Positive Leukemia with BCR-ABL Kinase Mutations before Allogeneic Transplantation Predominantly Relapse with the Same Mutation
- (2015) Daniel N. Egan et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Management of adult Ph-positive acute lymphoblastic leukemia
- (2015) S. Chiaretti et al. Hematology-American Society of Hematology Education Program
- Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia
- (2014) Avichai Shimoni et al. CANCER
- BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
- (2014) Matthew S. Zabriskie et al. CANCER CELL
- Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase
- (2014) Katerina Machova Polakova et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Maintenance therapy with dasatinib after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia
- (2013) Chieh-Lin Jerry Teng et al. ANNALS OF HEMATOLOGY
- Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain
- (2013) S. Soverini et al. BLOOD
- Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the fr
- (2013) Simona Soverini et al. CANCER
- Second-Generation Tyrosine Kinase Inhibitors Can Induce Complete Molecular Response in Ph-Positive Acute Lymphoblastic Leukemia After Allogeneic Stem Cell Transplant
- (2013) Carmen Fava et al. Clinical Lymphoma Myeloma & Leukemia
- Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease
- (2013) V Bachanova et al. LEUKEMIA
- Prophylactic post-transplant dasatinib administration in a pediatric patient with Philadelphia chromosome-positive acute lymphoblastic leukemia
- (2013) Akihiro Watanabe et al. PEDIATRICS INTERNATIONAL
- Prophylactic and Preemptive Therapy with Dasatinib after Hematopoietic Stem Cell Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
- (2012) Giovanni Caocci et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia
- (2012) H Pfeifer et al. LEUKEMIA
- Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia
- (2012) H Pfeifer et al. LEUKEMIA
- Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
- (2012) Jorge E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- BCR-ABL1 kinase domain mutations: Methodology and clinical evaluation
- (2011) Mary Alikian et al. AMERICAN JOURNAL OF HEMATOLOGY
- BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet
- (2011) S. Soverini et al. BLOOD
- Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis
- (2010) S. Soverini et al. HAEMATOLOGICA
- Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors
- (2009) S. Soverini et al. BLOOD
- Constant BCR-ABL transcript level ≥0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis
- (2009) Kateřina Machová Poláková et al. EXPERIMENTAL HEMATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started